On Thursday 4 March, the European Commission opened a formal antitrust investigation to assess whether Teva has illegally delayed the market entry and uptake of medicines that compete with Copaxone, its blockbuster multiple sclerosis drug. The Commission will investigate whether the company has abused a dominant market position in breach of EU competition rules.
Margrethe Vestager, Executive Vice-President in charge of competition policy, said: “We have decided to launch an in-depth...